Vesugen

Overview

Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), developed by Vladimir Kh. Khavinson and the team at the St. Petersburg Institute of Bioregulation and Gerontology. It is also spelled "Vezugen" in some Khavinson-group literature and is referenced under the designation "T-38" in at least one paper. In Russia it is marketed as a "biologically active food supplement" (BAFS), not a registered pharmaceutical. It is positioned as a vascular bioregulator peptide targeting vascular endothelial aging. Published PubMed literature amounts to roughly a dozen to two dozen papers depending on search criteria (10-27 depending on how the search is scoped), consisting mostly of in vitro cell studies and rodent research. Only two small, uncontrolled human observational studies exist: one in vasculogenic erectile dysfunction (n=41, PMID 25051774) and one in elderly patients with multiple comorbidities and organic brain syndrome (n=32, PMID 26390612). Nearly all data originates from the Khavinson research group; no independent Western randomized controlled trial (RCT) has been published, and the proposed DNA-binding/docking mechanism has essentially not been independently replicated in Western laboratories. A 2021 mouse Alzheimer's study (PMID 34071923) received a published correction in January 2025 (PMID 39861198) — the correction addressed a figure-duplication formatting error between Figures 5 and 8, and the authors state the scientific conclusions are unaffected; this correction should be noted whenever citing that study. Vialdyne releases Vesugen as a lyophilized tripeptide (linear) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.

Applications & buyer fit

Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

204271-66-9

Molecular Formula

C15H26N4O8

Molecular Weight

390.39 g/mol

Sequence

Lys-Glu-Asp

Appearance

White lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2 minutes

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108-114.
2. Khavinson VKh, Lin'kova NS, Evlashkina EV, Durnova AO, Kozlov KL, Gutop OE. Molecular aspects of anti-atherosclerotic effects of short peptides. Bull Exp Biol Med. 2014;158(1):159-163.
3. Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VKh, Dyakonov MM, Kozina LS. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646-650.
4. Chalisova NI, Lopatina NG, Kamishev NG, Linkova NS, Koncevaya EA, Dudkov AV, Kozina LS, Khavinson VKh, Titkov YuS. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012;153(4):569-572.
5. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151.
6. Khavinson VKh, Lin'kova NS, Umnov RS. Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease. Bull Exp Biol Med. 2021;171(2):190-193.

Frequently asked questions